Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01309490

Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients

An Open-label, Dose Escalation Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Expressing Elevated eIF4E

Sponsor: Jewish General Hospital

Conditions Malignant Solid Tumor

Interventions Ribavirin

Updated 5 times since 2017 Last updated: Jul 24, 2025 Started: Mar 17, 2011 Primary completion: Oct 29, 2014 Completion: Oct 29, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual, competing studies

Other terminated trials from Jewish General Hospital

See all terminations from Jewish General Hospital

Listed as NCT01309490, this PHASE1/PHASE2 trial focuses on Malignant Solid Tumor and remains terminated or withdrawn. Sponsored by Jewish General Hospital, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Aug 2025 — Present [monthly]

Terminated PHASE1/PHASE2

Status: Unknown → Terminated
Sep 2024 — Aug 2025 [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jewish General Hospital

Data source: Jewish General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada